{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T02:03:14Z","timestamp":1768010594537,"version":"3.49.0"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2017,12,19]],"date-time":"2017-12-19T00:00:00Z","timestamp":1513641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Boryung Pharmaceutical Company"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0189342","type":"journal-article","created":{"date-parts":[[2017,12,20]],"date-time":"2017-12-20T15:02:53Z","timestamp":1513782173000},"page":"e0189342","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Gender-specific differences in the incidence of microalbuminuria in metabolic syndrome patients after treatment with fimasartan: The K-MetS study"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5623-7010","authenticated-orcid":true,"given":"Jeong Bae","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-A","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ki-Chul","family":"Sung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jang Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,12,19]]},"reference":[{"issue":"17","key":"ref1","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute Scientific Statement","volume":"112","author":"SM Grundy","year":"2005","journal-title":"Circulation"},{"issue":"4","key":"ref2","first-page":"403","article-title":"Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies","volume":"49","author":"AS Gami","year":"2007"},{"issue":"2","key":"ref3","first-page":"385","article-title":"The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study","volume":"28","author":"AM McNeill","year":"2005"},{"issue":"25","key":"ref4","first-page":"3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report","volume":"106","year":"2002"},{"key":"ref5","first-page":"15","article-title":"International Obesity Task Force: Redefining Obesity and Its Treatment","year":"2000"},{"issue":"6","key":"ref6","first-page":"1463","article-title":"Is the diagnosis of metabolic syndrome useful for predicting cardiovascular disease in asian diabetic patients? Analysis from the Japan Diabetes Complications Study","volume":"28","author":"H Sone","year":"2005"},{"issue":"2","key":"ref7","first-page":"173","article-title":"Metabolic syndrome in subjects with essential hypertension: relationships with subclinical cardiovascular and renal damage","volume":"54","author":"G Mule","year":"2006"},{"issue":"4","key":"ref8","first-page":"683","article-title":"Cardiovascular morbidity and mortality associated with the metabolic syndrome","volume":"24","author":"BO Isomaa","year":"2001"},{"issue":"3","key":"ref9","first-page":"633","article-title":"Increased prevalence of metabolic syndrome among hypertensive population: ten years' trend of the Korean National Health and Nutrition Examination Survey","volume":"166","author":"SR Lee","year":"2013"},{"issue":"2","key":"ref10","first-page":"362","article-title":"Metabolic syndrome: recent prevalence in East and Southeast Asian populations","volume":"16","author":"P Nestel","year":"2007"},{"issue":"4","key":"ref11","first-page":"276","article-title":"The metabolic syndrome in East Asians","volume":"2","author":"KC Hoang","year":"2007"},{"issue":"3","key":"ref12","first-page":"1142","article-title":"Metabolic syndrome: prevalence and risk factors in southern China","volume":"38","author":"JB Li","year":"2010"},{"issue":"2","key":"ref13","first-page":"65","article-title":"Disparities in the Prevalence of Metabolic Syndrome (MS) and its Components Among University Employees by Age, Gender and Occupation","volume":"8","author":"MJ Cheserek","year":"2014"},{"issue":"2","key":"ref14","first-page":"163","article-title":"Prevalence of the metabolic syndrome in drug-treated hypertensive patients and control subjects","volume":"245","author":"AO Rantala","year":"1999"},{"issue":"13","key":"ref15","first-page":"905","article-title":"Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study","volume":"342","author":"TW Gress","year":"2000"},{"issue":"2","key":"ref16","first-page":"353","article-title":"Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"31","author":"HR Black","year":"2008"},{"issue":"1","key":"ref17","first-page":"247","article-title":"Antihypertensive therapy and incidence of type 2 diabetes: a systematic review","volume":"27","author":"R Padwal","year":"2004"},{"issue":"9311","key":"ref18","first-page":"995","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"B Dahl\u00f6f","year":"2002"},{"issue":"9311","key":"ref19","first-page":"1004","article-title":"Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"LH Lindholm","year":"2002"},{"issue":"5","key":"ref20","first-page":"821","article-title":"Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers for Prevention of Type 2 DiabetesA Meta-Analysis of Randomized Clinical Trials","volume":"46","author":"H Abuissa","year":"2005"},{"issue":"3\u20134","key":"ref21","first-page":"177","article-title":"The Efficacy of Fimasartan for Cardiovascular Events and Metabolic Syndrome (K-MetS Study): Rationale, Design and Participant Characteristics","volume":"1","author":"C Kim","year":"2014"},{"issue":"16","key":"ref22","first-page":"1640","article-title":"Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity","volume":"120","author":"KG Alberti","year":"2009"},{"issue":"6","key":"ref23","first-page":"1323","article-title":"Increasing prevalence of metabolic syndrome in Korea: the Korean National Health and Nutrition Examination Survey for 1998\u20132007","volume":"34","author":"S Lim","year":"2011"},{"issue":"6","key":"ref24","first-page":"1547","article-title":"Prospective study of serum adiponectin and incident metabolic syndrome: the ARIRANG study","volume":"36","author":"JY Kim","year":"2013"},{"issue":"5","key":"ref25","first-page":"315","article-title":"The role of Angiotensin receptor blocker and calcium channel blocker combination therapy in treating hypertension: focus on recent studies","volume":"10","author":"SG Chrysant","year":"2010"},{"issue":"12","key":"ref26","first-page":"861","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"BM Brenner","year":"2001"},{"issue":"11","key":"ref27","first-page":"1090","article-title":"Gender differences in the effects of angiotensin receptor blockers on cardiovascular disease","volume":"17","author":"H Yoshida","year":"2011"},{"issue":"3","key":"ref28","first-page":"672","article-title":"Renin angiotensin system and gender differences in the cardiovascular system","volume":"53","author":"M Fischer","year":"2002"},{"issue":"6","key":"ref29","first-page":"687","article-title":"Gender and the renin-angiotensin-aldosterone system","volume":"24","author":"K Komukai","year":"2010"},{"issue":"3","key":"ref30","first-page":"413","article-title":"Estrogen and angiotensin II interactions determine cardio-renal damage in Dahl salt-sensitive rats with heart failure","volume":"28","author":"R Hoshi-Fukushima","year":"2008"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0189342","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T10:41:53Z","timestamp":1540032113000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0189342"}},"subtitle":[],"editor":[{"given":"Tatsuo","family":"Shimosawa","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,12,19]]},"references-count":30,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2017,12,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0189342","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,19]]}}}